Promore Pharma: Waiting For Clinical Data
Redeye maintains its fair value range following Promore’s Q1’20 report. The report did not include any major surprises and the top-line data from the ongoing LL-37 study is, in our opinion, the most significant catalyst for the stock in 2020.